C - Chemistry – Metallurgy – 12 – N
Patent
C - Chemistry, Metallurgy
12
N
C12N 5/10 (2006.01) A61K 35/14 (2006.01) A61K 39/00 (2006.01) A61K 39/385 (2006.01) C12N 5/22 (2006.01) C12N 15/07 (2006.01) A61K 38/00 (2006.01)
Patent
CA 2265925
An isolated cell or cell line, wherein the cell is .beta.2-microglobulin deficient, neomycin-resistant and HAT-sensitive is provided. The cell FO-1 #12 is an example of a cell having these characteristics. A cell hybrid formed by the fusion of an FO-1 #12 cell or other cell described herein and a mammalian cell is provided. The patient-derived cell can be a tumor cell or other cell, such as a white blood cell. The patient-derived tumor cell can be a melanoma cell, a prostatic carcinoma cell, a colon carcinoma cell, a lung carcinoma cell, a breast carcinoma cell, a pancreatic carcinoma cell, or others. A method of treating AIDS in a patient, comprising administering to the patient a cell hybrid provided herein, wherein the patient-derived white blood cell is derived from the patient being treated, is provided. A method of treating solid tumor in a patient, comprising administering to the patient a cell hybrid as provided herein, wherein the patient-derived tumor cell is derived from the patient being treated, is provided.
L'invention porte sur une cellule ou une lignée de cellules isolées caractérisées par leur déficience en .beta.2-microglobuline, leur résistance à la néomycine et leur sensibilité au HAT. La cellule FO-1 #12 en est un exemple. L'invention porte également sur un hybride de cellule résultant de la fusion d'une cellule FO-1 #12 ou d'autres cellules et d'une cellule de mammifère. La cellule provenant d'un patient peut être tumorale ou autre, par exemple un leucocyte. Ladite cellule tumorale peut provenir d'un mélanome, d'un carcinome de la prostate, d'un carcinome du colon, d'un carcinome des poumons, d'un carcinome du sein, d'un carcinome du pancréas ou autres. L'invention porte en outre sur un procédé de traitement consistant à administrer au patient un hybride de cellule ainsi obtenu à partir de leucocytes du patient traité, et sur un procédé de traitement des tumeurs solides consistant à administrer au patient un hybride de cellule ainsi obtenu à partir de cellules du patient traité.
Gattoni-Celli Sebastiano
Mcclay Edward F.
Newton Danforth A. III
Gowling Lafleur Henderson Llp
Medical University Of South Carolina
LandOfFree
Semi-allogeneic cell hybrids as preventive and therapeutic... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Semi-allogeneic cell hybrids as preventive and therapeutic..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Semi-allogeneic cell hybrids as preventive and therapeutic... will most certainly appreciate the feedback.
Profile ID: LFCA-PAI-O-1659409